Sandoz reported a 9% growth in net sales of generics and biosimilars to third parties for 2024, marking a strong first ...

Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the ...

Biocon Biologics has partnered with Civica to improve access to and affordability of insulin aspart in the U.S. Biocon will ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), today announced the successful results of a pivotal Phase 3, ...

Biocon Biologics, one of India's leading biologic drug manufacturers, announced on Friday the results of a Phase-3 study on a ...

Biocon Biologics partners with Civica to enhance access to Insulin Aspart in the US, no tech transfer involved.

This collaboration is in addition to Biocon Biologics’ own insulin aspart drug product for the US, which is currently under ...

Biocon Biologics partners with Civica Inc to increase affordability and access to Insulin Aspart in the US, targeting the ...

Civica will commercialize the medicine for patients in the United States, after completion of development work and clinical ...

Christopher Ridley, a spokesperson for Moderna, said the state legislative efforts are largely a product of ...

BRIDGEWATER, N.J., and BENGALURU, India, March 7, 2025 /PRNewswire/ -- Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd. (BSE code ...

The company announced that it has secured three orders valued at around ₹500 crore from Power Grid Corporation of India Ltd ...